Roche's Columvi therapy showed 41% reduction in risk of death for DLBCL patients

From GlobeNewswire: 2024-06-15 10:00:00

A recent study by Roche revealed that their Columvi combination therapy showed a 41% reduction in the risk of death for people with relapsed or refractory DLBCL. The data, presented at the EHA 2024 Congress, highlighted the potential of this treatment option for patients who are not candidates for transplant. Results from the Phase III STARGLO study showed a statistically significant improvement in overall survival and progression-free survival with the Columvi combination. This treatment could offer hope for patients with limited options in managing this aggressive form of lymphoma. Regional variations were noted, but further research is needed to interpret these findings accurately.



Read more at GlobeNewswire: Roche’s Phase III STARGLO study demonstrates Columvi